arrow
M

Myriam Chalabi

the netherlands cancer institute
H指数:26
被引数:7,376

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Making sense of TILs : recommendations for morphological assessment of tumour‐infiltrating lymphocytes in colorectal carcinoma: a report on behalf of the International Immuno‐Oncology Biomarker Working Group

理解肿瘤浸润淋巴细胞:<scp>TILs</scp>:结直肠癌中肿瘤浸润淋巴细胞形态学评估的建议——国际免疫肿瘤生物标志物工作组报告

2026-11-030
PRE
Making sense of TILs: recommendations for morphological assessment of tumour-infiltrating lymphocytes in gastro-oesophageal carcinoma

理解TILs: 胃食管癌中肿瘤浸润淋巴细胞形态学评估的建议

2026-02-050
OAAI
Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study

能否通过观察等待或经肛微创手术来保留直肠,作为短期放疗联合局部或全身治疗的早期直肠癌的附加治疗?STARTREC-3方案:一项非随机、多中心、II期平台研究的方案

2025-12-160
PRE
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers

错配修复功能 proficient 结直肠癌的新辅助免疫疗法

Nature
IF48.5
2025-10-200
PRE
Incidence and Outcomes of Patients With Mismatch Repair Deficient Rectal Cancer Operated in 2016: A Nationwide Cohort From The Netherlands

错配修复缺陷型直肠癌患者手术治疗的发病率和结局:一项来自荷兰的全国性队列研究

2024-12-100
OAAI
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer
2024-11-281
PRE
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
2024-09-150
OAAI
Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2

局部晚期MMR-deficient结肠癌的新辅助免疫疗法:NICHE-2研究3年无病生存率

2024-09-013
PRE
Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study

新辅助纳武利尤单抗(nivo)联合雷利利尤单抗(rela)在微卫星不稳定性高结肠癌中的研究:NICHE-3研究的结果

2024-09-012
PRE
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer
2024-06-0634
PRE
Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
2024-06-010
PRE
Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
2024-03-061
OAAI
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

新辅助阿特珠单抗联合化疗治疗胃和胃食管交界处腺癌: 2期熊猫试验

2024-01-0830
OAAI